Laurus Labs Ltd Thursday said its profit after tax for the quarter ended on December 31 was down by 49 per cent to Rs 17.8 crore against Rs 34.9 crore during the same quarter last fiscal.
According to a press release issued by the drug maker, revenues from operations stood at Rs 529.5 crore up 10.6 per cent.
The same was Rs 478.9 crore in Q3 FY18.
CEO of Laurus Labs, Satyanarayana Chava said, "We delivered healthy revenue growth of 11 per cent this quarter and for 9M FY19, driven by growth in our Synthesis, and Generic API portfolio.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app